12:00 AM
Feb 07, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Buspirone: Began Phase III trial

Biovail Corp. International (BVF; TSE:BVF), Toronto, Ontario
Product: Buspirone
Business: Neurological
Therapeutic category: Neurotransmission
Target: Serotonin...

Read the full 57 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >